The Use of probiotics prior to liver transplant should be conside

The Use of probiotics prior to liver transplant should be considered as a part of the transplant protocol. Disclosures: The following people have nothing to disclose: Tarek Sawas, Shadi Al Halabi, Mubarak W. Sayyar, Won Kyoo Cho Several factors have been reported

to influence the survival outcome following liver transplantation. The principal six identified variables that influence outcomes are the transplant center’s experience and outcome statistics, recipient age, donor age, gender, MELD score, and liver disease etiology. The aim of this study was to compare the most recent outcome data from United States liver transplant centers which have performed at least 50 Liver Transplants (LT) per year. Methods/Results: Data were collected from the Scientific Selleck PLX3397 Registry see more of Transplant Recipients (www.SRTR.org) and the data was compared between the liver transplant centers in the US. The parameters assessed included but were not limited to: 3-year graft survival, 3-year patient survival, wait list mortality, composite 3-year mortality. Despite adjusting for all of the main variables, it was apparent that major differences in the three-year patient survival at liver transplant centers in the

US varied widely and ranged from 60-94% with a national average of approximately 79%. Wait list mortality also varied (10 folds) from a value 0.04% at the better performing LT centers to 0.40% in the poorer performing centers. Furthermore, the composite 3-year mortality rate range varied from 17.6- 67.0%. This Inositol monophosphatase 1 large variation in 3-year patient survival outcome between US LT centers performing more than 50 LT per year could not be explained after adjusting for the identified predictive variables and was not related to the level of competitiveness between centers or the centers’ access to organs. Importantly, performing < 50 liver transplantation per year was not found to correlate negatively with the 3-year patient survival data. Based upon these data obtained from the SRTR, it can be concluded that: 1) post- transplant survival varies widely between US liver transplant centers; 2) a favorable outcome is not predicted by: a) the

number of liver transplants performed, b) the various patient and donor characteristics examined, c) the MELD score, or d) the availability of organs for the individual transplant center. 3) The practice of substituting less toxic immunosuppressive agents at some centers was positively associated with a better overall 3-year survival outcome. These data suggest that the hospital and transplant team skills are the most important factors that contribute to the marked variation in adjusted post- LT survival between centers. Factors that may reduce this variation between centers in the future potentially consist of: 1) Standardization of the protocols used for the management of pre- and post-LT care. 2) Consideration for the use of less toxic and lower doses of immunosuppression.

Comments are closed.